BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 12:19:00 PM | Browse: 1122 | Download: 1359
Publication Name World Journal of Cardiology
Manuscript ID 11325
Country/Territory India
Received
2014-05-15 20:25
Peer-Review Started
2014-05-15 23:03
To Make the First Decision
2014-06-27 12:03
Return for Revision
2014-07-04 12:13
Revised
2014-07-07 15:10
Second Decision
2014-08-31 16:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-08-31 17:16
Articles in Press
2014-08-31 17:16
Publication Fee Transferred
Edit the Manuscript by Language Editor
2014-09-03 20:39
Typeset the Manuscript
2014-10-27 14:59
Publish the Manuscript Online
2014-11-05 09:45
ISSN 1949-8462 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Cardiac & Cardiovascular Systems
Manuscript Type Review
Article Title Mitochondria-targeted agents: Future perspectives of mitochondrial pharmaceutics in cardiovascular diseases
Manuscript Source Invited Manuscript
All Author List Thekkuttuparambil Ananthanarayanan Ajith and Thankamani Gopinathan Jayakumar
Funding Agency and Grant Number
Corresponding Author Thekkuttuparambil Ananthanarayanan Ajith, PhD, Professor, Department of Biochemistry, Amala Institute of Medical Sciences, Amala Nagar, Thrissur 680 555, Kerala, India. taajith@rediffmail.com
Key Words Cardiovascular diseases; Oxidative stress; Antioxidant; Electron transport chain; Mitochondrial medicine; Heart failure
Core Tip Dysfunction of mitochondria increases the risk for a large number of human diseases, including cardiovascular diseases. Heart failure (HF) following ischemic heart disease, infantile cardiomyopathy and cardiac hypertrophy associated with left ventricular dilations are some of the cardiovascular diseases in which the role of mitochondrial oxidative stress has been reported. Recent reports on chronic HF followed by ischemic heart disease suggested a reduced supply of energy necessary for the contractile function of cardiomyocytes. Since mitochondrial damages are central to the pathophysiology of HF, various approaches are used to target compounds at mitochondria alone or adjunct to standard therapies.
Publish Date 2014-11-05 09:45
Citation Ajith TA, Jayakumar TG. Mitochondria-targeted agents: Future perspectives of mitochondrial pharmaceutics in cardiovascular diseases. World J Cardiol 2014; 6(10): 1091-1099
URL http://www.wjgnet.com/1949-8462/full/v6/i10/1091.htm
DOI http://dx.doi.org/10.4330/wjc.v6.i10.1091
Full Article (PDF) WJC-6-1091.pdf
Full Article (Word) WJC-6-1091.doc
Manuscript File 11325-Review.doc
Answering Reviewers 11325-Answering reviewers.pdf
Copyright License Agreement 11325-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 11325-Language certificate.pdf
Peer-review Report 11325-Peer review(s).pdf
Scientific Misconduct Check 11325-CrossCheck.jpg
Scientific Editor Work List 11325-Scientific editor work list.pdf